Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer

Cancer Investigation

Volumn 21, Issue 4, 2003, Pages 517-525

  Dabrow, Michael B ^a,c   Francesco, Michelle R ^b   Gilman, Paul B ^b   Cantor, Ronald ^a   Rose, Lewis ^a   Meyer, Thomas J ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b LANKENAU HOSPITAL   (United States)

^c UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; NEUTROPENIA; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SURVIVAL ANALYSIS; TOPOTECAN; TREATMENT OUTCOME;

EID: 0141788630     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120022363     Document Type: Article

References (22)

1. Greenlee, R.T.; Murray, T.; Bolden, S.; Wingo, P.A. Cancer statistics, 2000 CA: Cancer J. Clinicians 2000, 50, 7-33.
2. Ginsberg, R.J.; Kris, M.G.; Armstrong, J.G. Cancer of the Lung. In Principles and Practice of Oncology; Devita, V.T., Jr., Hellman, S., Rosenberg, S.A., Eds.; Lippincott-Raven: Philadelphia, 1997; 849-877.
3. Jaxel, C.; Kohn, K.W.; Wani, M.C.; Wall, M.E.; Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerse I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. 1989, 49, 1465-1469.
4. Chen, Y,A.; Liu, L.F. DNA Topoisomerases: essential enzymes and lethal targets. Ann. Rev. Pharmacol. Toxicol. 1994, 34, 191-218.
5. Johnson, R.K.; McCabe, F.L.; Gallagher, G.; Wood, J.; Galet, J.; Hertzberg, R.P. Comparative Efficacy of Topotecan, Irinotecan, Camptothecin and 9-Aminocamptothecin in Preclinical Tumor Models. In Proc Seventh NCI-EORTC Symposium on New Drugs in Cancer Therapy. Amsterdam, 1992; (abstract 85).
6. Houghton, P.J.; Cheshire, P.J.; Myers, L.; Stewart, C.F.; Synold, T.W.; Houghton, J.A. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemotherapy Pharmacol. 1992, 31, 229-239.
7. Wall, J.G.; Burris, H.A.; von Hoff, D.D.; Rodriguez, G.; Kneaper-Hall, R.; Shaffer, D.; O'Rourke, T.; Brown, T.; Weiss, G.; Clark, G.; McVea, S.; Brocon, J.; Johnson, R.; Friedman, C.; Smith, B.; Mann, W.S.; Kuhn, J. A phase I clinical and pharmacokinetic study of the topoisomerase i inhibitor topotecan (SK + F 104864) Given as an intravenous bolus every 21 days. Anticancer Drugs 1992, 3, 337.
8. Haas, N.; LaCreta, F.P.; Walzak, J.; Hudes, G.R.; Brennan, J.M.; Ozols, R.F.; O'Dwyer, P.J. Phase I/pharmacokinetic study of topotecan by 24 hour continuous infusion weekly. Cancer Res. 1994, 54, 1220-1226.
9. Van Warmerdam, L.J.C.; ten Bakkel Huinink, W.W.; Rodenhuis, S.; Koier, I.; Davies, B.E.; Rosing, H.; Maes, R.A.A.; Beijnin, J.H. Phase I clinical and pharmacokinetic study of topotecan administered by a 24 hour continuous infusion. J. Clin. Oncol. 1995, 13, 1768-1776.
10. Abbruzzese, J.L.; Madden, T.; Sugarman, S.M.; Ellis, A.I.; Loughlin, S.; Hess, K.R.; Newman, R.A.; Zwelling, L.A.; Raber, M.N. Phase I. clinical and plasma and cellular pharmacologic study of topotecan without and with granulocyte colony stimulating factor. Clin. Cancer Res. 1996, 2, 1489-1497.
11. Lynch, T.J.; Kalish, L.; Strauss, G.; Elias, A.; Skarin, A.; Shulman, L.N.; Posner, M.; Frei, E. Phase II. study of topotecan in metastatic non small cell lung cancer. J. Clin. Oncol. 1994, 12, 347-352.
12. Perez-Soler, R.; Fossella, F.V.; Glisson, B.S.; Lee, J.S.; Murphy, W.K.; Shin, D.M.; Kemp, B.L.; Lee, J.J.; Kane, J.; Robinson, R.A.; Lippman, S.M.; Kurie, J.M.; Huber, M.H.; Raber, M.N.; Hong, W.K. Phase II study of topotecan in patients with advanced non small cell lung cancer previously untreated with chemotherapy. J. Clin. Oncol. 1996, 9, 503-513.
13. Abbrazzese, J.L.; Granewald, R.; Weeks, E. A.; Gravel, D.; Adams, T.; Nowak, B.; Mineishi, S.; Tarassoff, P.; Satterlee, W.; Raber, M.N.; Plunkett, W. Phase I clinical plasma and cellular pharmacology study of gemcitabine. J. Clin. Oncol. 1991, 9, 491-498.
14. Abratt, R.P.; Bezwoda, W.R.; Falkson, G. Efficacy and safety of gemcitabine on non small cell lung cancer: a phase II trial. J. Clin. Oncol. 1994, 12, 1535-1540.
15. Anderson, H.; Lund, B.; Bach, F. Single Agent Activity of Weekly Gemcitabine in Advanced Non Small Cell Lung Cancer: A Phase II Study. J. Clin. Oncol. 1994, 12, 1821-1826.
16. Gatzemeier, U.; Shepherd, F.A.; LeChevalier, T. Activity of gemcitabine in patients with non small cell lung cancer: a multicenter extended phase II study. Europ. J. Cancer. 1996, 32, 243-248.
17. Fossella, F.V.; Lippman, S.M.; Shin, D.M.; Tarassoff, P.; Calayag-Jung, M.; Perez-Soler, R.; Lee, J.S.; Murphy, W.K.; Glisson, B.; Rivera, E.; Hong, W.K. Maximum tolerated dose defined for single agent gemcitabine: a phase I dose escalation study in chemotherapy naïve patients with advanced non small cell lung cancer. J. Clin. Oncol. 1997, 15, 310-316.
18. Rinaldi, D.; Lormand, N.; Brierre, J.; Cole, J.; Barnes, B.; Fontenot, F.; Buller, E.; Rainey, J. A phase I-II trial of topotecan and gemcitabine in patients with previously treated advanced non-small cell lung cancer. Cancer Invest. 2001, 19, 467-474.
19. Dabrow, M.B.; Francesco, M.R.; McBrearty, F.X.; Caradonna, S. The Effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynec. Oncol. 1998, 71, 29-37.
20. Berembaum, M.C. Criteria for analyzing interaction between biologically active agents. Adv. Cancer Res. 1981, 25, 269-335.
21. AJCC Cancer Staging Manual. Fleming, I.D., Cooper, J.S., Henson, D.E., Hutter, R.V., Kennedy, B.J., Murphy, G.P., O'Sullivan, B., Sobin, L.H., Yarbro, J.W., Eds.; Lippincott-Raven: Philadelphia, 1997; 117-127.
22. Schiller, J.H.; Harrington, D.; Sandler, A.B.; Belani, C.; Langer, C.J.; Krook, J.E.; Johnson, D.H. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N. Eng. J. Med. 2002, 346, 92-98.